Test Price
3,000 AED✅ Home Collection Available
Neuromuscular Panel (NGS) Genetic Test in UAE | 3000 AED | DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Precision: 99.9% analytic sensitivity across 200+ neuromuscular genes via ISO 9001:2015 certified NGS sequencing and AI-driven bioinformatic pipeline.
- Specimen Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – available daily from 8 AM to 11 PM across all UAE emirates.
- Post-Test Support: Complimentary telephonic consultation with a DHA-licensed Consultant Medical Geneticist to interpret results and guide clinical management.
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Comprehensive Genetic Screening for Inherited Neuromuscular Disorders
This targeted NGS panel simultaneously sequences the coding regions and splice sites of over 200 genes associated with inherited neuromuscular conditions, including muscular dystrophies, spinal muscular atrophies, hereditary motor and sensory neuropathies, congenital myasthenic syndromes, and metabolic myopathies. Validated on the Illumina NovaSeq platform with AI-driven variant interpretation per ACMG guidelines, the assay delivers a definitive molecular diagnosis in a single workflow, eliminating the need for sequential single-gene testing and reducing time to diagnosis.
| Feature | Our NGS Panel (DNA Labs UAE) | Conventional Single-Gene Sequencing |
|---|---|---|
| Analytic Sensitivity | 99.9% across 200+ genes | ≤80% per gene; limited to 1–5 genes |
| Methodology | Illumina NovaSeq NGS + AI variant interpretation (ACMG 2023 guidelines) | Sanger sequencing; manual curation |
| Turnaround Time | 3–4 Weeks | 2–4 weeks per gene; cumulative months for multi-gene assessment |
| Clinical Integration | Pre-test genetic counselling & post-test specialist consultation included | Typically separate counselling at additional cost |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I recognise that unexplained muscle weakness, elevated creatine kinase, or a family history of neuromuscular disease can be deeply concerning. This comprehensive NGS panel provides a high-resolution genetic blueprint that can confirm or exclude a wide spectrum of hereditary neuromuscular conditions. However, every result must be interpreted within the full clinical context, including a detailed three-generation pedigree and neurological examination findings. Variants of uncertain significance may require segregation analysis in family members before clinical action is taken.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication and Clinical Precautions
Do not alter, pause, or discontinue any prescribed neurological medication—such as anticonvulsants, immunosuppressants, or disease-modifying therapies—based on preliminary genetic findings without direct oversight from your treating physician. Genetic test results may reveal variants that necessitate confirmatory biochemical or electrophysiological studies before management changes are implemented.
Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not intended for asymptomatic minors without prior formal genetics consultation and documented parental consent, in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability. It is not a substitute for emergency medical assessment.
- Exclusion: Individuals who are unable to provide valid informed consent, or those with a known haematological malignancy requiring bone marrow biopsy within the preceding four weeks, should defer testing until cleared by their haematologist.
- Emergency Red Flags: If you experience sudden respiratory distress, acute onset limb paralysis, severe bulbar dysfunction (choking, dysphagia, slurred speech), or loss of consciousness, proceed to the nearest emergency department immediately – do not await genetic test results before seeking acute care.
Patient FAQ & Clinical Guidance
1. What conditions does the neuromuscular genetic panel detect?
The panel interrogates 200+ genes associated with a broad spectrum of inherited neuromuscular disorders, including Duchenne and Becker muscular dystrophies, spinal muscular atrophy, Charcot-Marie-Tooth disease, congenital myasthenic syndromes, and metabolic myopathies. The comprehensive design captures coding exons, splice sites, and selected intronic regions to maximise diagnostic yield for both common and rare genotypes.
2. How is the blood sample collected and what logistics are involved?
A standard peripheral whole blood sample (two EDTA tubes, 6 mL total) is collected by our certified phlebotomist via VIP Mobile Phlebotomy with full temperature-controlled cold-chain transport, available daily from 8 AM to 11 PM across Dubai, Abu Dhabi, and all UAE emirates. The sample is delivered to our CAP-accredited laboratory within four hours of collection, and you receive a confirmation message via WhatsApp along with a unique tracking ID.
3. What is the turnaround time and what post-test support is provided?
Results are reported within 3–4 weeks from sample receipt, followed by a complimentary telephonic consultation with a DHA-licensed Consultant Medical Geneticist who explains the findings, their clinical implications, and recommended next steps. You will receive a detailed interpretive report compliant with ACMG variant classification guidelines, and our clinical care team remains available for follow-up questions via phone or secure messaging.
UAE Regulatory & Data Privacy Adherence
All genetic data generated by this NGS panel is processed, stored, and transmitted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genetic information is encrypted at rest and in transit, access is restricted to authorised clinical personnel only, and no data is shared with third parties without your explicit written consent. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is a DHA-licensed diagnostic facility (License No. 1143) operating under the regulatory oversight of the Dubai Healthcare City Authority of the United Arab Emirates.
Clinical & Logistical Metadata
| Test Name | Neuromuscular Panel (NGS) Genetic Test |
| Price (AED) | 3,000 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA tube) |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina NovaSeq 6000 |
| ICD-10-CM Code | G71.0, G71.9, G12.9, G60.9, G70.9 |
| LOINC Code | 101247-9 |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians